KRAS and non-small cell lung carcinoma: We chose three compounds with reported efficacy in preclinical studies on Kras‐driven NSCLC 14, 25, namely the dual PI3K and mTOR inhibitor NVP‐BEZ235 or dact, the MEK inhibitor AZD6244 or sel, and the SRC inhibitor sar (Figure 3A).